Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions

Luis Souhami, Robert Corns, Marie Duclos, Lorraine Portelance, Boris Bahoric, Gerald Stanimir

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives. To evaluate the long-term treatment outcome of patients with carcinoma of the cervix treated with high dose rate brachytherapy (HDRB) using a small number of fractions. Methods. Between 1984 and 1997, 282 patients with cervix cancer (stages IB to IVA) were treated with external beam radiotherapy to the whole pelvis (median dose of 45 Gy) and HDRB (median dose of 24 Gy at point A in 3 insertions given weekly). Endpoints assessed were survival, patterns of failure and complications. Multivariate analysis was performed to identify variables predictive for overall survival and local control. Variables investigated were stage, age, overall duration of treatment, HDRB scheduling and total dose to point A. Results. At a median follow-up of 86.3 months for patients at risk, the 5-, 10- and 15-year overall survival rates are 57%, 52% and 47%, respectively. On multivariate analysis, only stage and age correlated with improved survival. Treatment duration beyond 47 days was associated with poorer overall survival, although it did not reach statistical significance (P = 0.10). Brachytherapy scheduling and BED to point A had no impact on overall survival. Stage and age significantly correlated with pelvic disease control. Duration of therapy, scheduling of the brachytherapy and BED at point A were not individual predictors for overall local control. Overall, gastrointestinal and genitourinary actuarial complication rates were 15% and 8%, respectively. Conclusions. In our experience, HDRB using 3 insertions is well tolerated and the results are comparable to HDRB using larger number of fractions and to low dose rate brachytherapy.

Original languageEnglish
Pages (from-to)508-513
Number of pages6
JournalGynecologic Oncology
Volume97
Issue number2
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Brachytherapy
Uterine Cervical Neoplasms
Survival
Multivariate Analysis
Pelvis
Cervix Uteri
Radiotherapy
Therapeutics
Survival Rate
Carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. / Souhami, Luis; Corns, Robert; Duclos, Marie; Portelance, Lorraine; Bahoric, Boris; Stanimir, Gerald.

In: Gynecologic Oncology, Vol. 97, No. 2, 01.05.2005, p. 508-513.

Research output: Contribution to journalArticle

Souhami, Luis ; Corns, Robert ; Duclos, Marie ; Portelance, Lorraine ; Bahoric, Boris ; Stanimir, Gerald. / Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions. In: Gynecologic Oncology. 2005 ; Vol. 97, No. 2. pp. 508-513.
@article{3aa0286b2b0b44b5896ec4565cd92828,
title = "Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions",
abstract = "Objectives. To evaluate the long-term treatment outcome of patients with carcinoma of the cervix treated with high dose rate brachytherapy (HDRB) using a small number of fractions. Methods. Between 1984 and 1997, 282 patients with cervix cancer (stages IB to IVA) were treated with external beam radiotherapy to the whole pelvis (median dose of 45 Gy) and HDRB (median dose of 24 Gy at point A in 3 insertions given weekly). Endpoints assessed were survival, patterns of failure and complications. Multivariate analysis was performed to identify variables predictive for overall survival and local control. Variables investigated were stage, age, overall duration of treatment, HDRB scheduling and total dose to point A. Results. At a median follow-up of 86.3 months for patients at risk, the 5-, 10- and 15-year overall survival rates are 57{\%}, 52{\%} and 47{\%}, respectively. On multivariate analysis, only stage and age correlated with improved survival. Treatment duration beyond 47 days was associated with poorer overall survival, although it did not reach statistical significance (P = 0.10). Brachytherapy scheduling and BED to point A had no impact on overall survival. Stage and age significantly correlated with pelvic disease control. Duration of therapy, scheduling of the brachytherapy and BED at point A were not individual predictors for overall local control. Overall, gastrointestinal and genitourinary actuarial complication rates were 15{\%} and 8{\%}, respectively. Conclusions. In our experience, HDRB using 3 insertions is well tolerated and the results are comparable to HDRB using larger number of fractions and to low dose rate brachytherapy.",
author = "Luis Souhami and Robert Corns and Marie Duclos and Lorraine Portelance and Boris Bahoric and Gerald Stanimir",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.ygyno.2005.02.015",
language = "English",
volume = "97",
pages = "508--513",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions

AU - Souhami, Luis

AU - Corns, Robert

AU - Duclos, Marie

AU - Portelance, Lorraine

AU - Bahoric, Boris

AU - Stanimir, Gerald

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Objectives. To evaluate the long-term treatment outcome of patients with carcinoma of the cervix treated with high dose rate brachytherapy (HDRB) using a small number of fractions. Methods. Between 1984 and 1997, 282 patients with cervix cancer (stages IB to IVA) were treated with external beam radiotherapy to the whole pelvis (median dose of 45 Gy) and HDRB (median dose of 24 Gy at point A in 3 insertions given weekly). Endpoints assessed were survival, patterns of failure and complications. Multivariate analysis was performed to identify variables predictive for overall survival and local control. Variables investigated were stage, age, overall duration of treatment, HDRB scheduling and total dose to point A. Results. At a median follow-up of 86.3 months for patients at risk, the 5-, 10- and 15-year overall survival rates are 57%, 52% and 47%, respectively. On multivariate analysis, only stage and age correlated with improved survival. Treatment duration beyond 47 days was associated with poorer overall survival, although it did not reach statistical significance (P = 0.10). Brachytherapy scheduling and BED to point A had no impact on overall survival. Stage and age significantly correlated with pelvic disease control. Duration of therapy, scheduling of the brachytherapy and BED at point A were not individual predictors for overall local control. Overall, gastrointestinal and genitourinary actuarial complication rates were 15% and 8%, respectively. Conclusions. In our experience, HDRB using 3 insertions is well tolerated and the results are comparable to HDRB using larger number of fractions and to low dose rate brachytherapy.

AB - Objectives. To evaluate the long-term treatment outcome of patients with carcinoma of the cervix treated with high dose rate brachytherapy (HDRB) using a small number of fractions. Methods. Between 1984 and 1997, 282 patients with cervix cancer (stages IB to IVA) were treated with external beam radiotherapy to the whole pelvis (median dose of 45 Gy) and HDRB (median dose of 24 Gy at point A in 3 insertions given weekly). Endpoints assessed were survival, patterns of failure and complications. Multivariate analysis was performed to identify variables predictive for overall survival and local control. Variables investigated were stage, age, overall duration of treatment, HDRB scheduling and total dose to point A. Results. At a median follow-up of 86.3 months for patients at risk, the 5-, 10- and 15-year overall survival rates are 57%, 52% and 47%, respectively. On multivariate analysis, only stage and age correlated with improved survival. Treatment duration beyond 47 days was associated with poorer overall survival, although it did not reach statistical significance (P = 0.10). Brachytherapy scheduling and BED to point A had no impact on overall survival. Stage and age significantly correlated with pelvic disease control. Duration of therapy, scheduling of the brachytherapy and BED at point A were not individual predictors for overall local control. Overall, gastrointestinal and genitourinary actuarial complication rates were 15% and 8%, respectively. Conclusions. In our experience, HDRB using 3 insertions is well tolerated and the results are comparable to HDRB using larger number of fractions and to low dose rate brachytherapy.

UR - http://www.scopus.com/inward/record.url?scp=18144362480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18144362480&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.02.015

DO - 10.1016/j.ygyno.2005.02.015

M3 - Article

C2 - 15863152

AN - SCOPUS:18144362480

VL - 97

SP - 508

EP - 513

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -